HUP0400566A3 - Pharmaceutical preparation comprising an active dispersed on a matrix - Google Patents
Pharmaceutical preparation comprising an active dispersed on a matrixInfo
- Publication number
- HUP0400566A3 HUP0400566A3 HU0400566A HUP0400566A HUP0400566A3 HU P0400566 A3 HUP0400566 A3 HU P0400566A3 HU 0400566 A HU0400566 A HU 0400566A HU P0400566 A HUP0400566 A HU P0400566A HU P0400566 A3 HUP0400566 A3 HU P0400566A3
- Authority
- HU
- Hungary
- Prior art keywords
- matrix
- pharmaceutical preparation
- active dispersed
- dispersed
- active
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00126847 | 2000-12-07 | ||
PCT/EP2001/014307 WO2002045693A1 (en) | 2000-12-07 | 2001-12-06 | Pharmaceutical preparation comprising an active dispersed on a matrix |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0400566A2 HUP0400566A2 (hu) | 2004-06-28 |
HUP0400566A3 true HUP0400566A3 (en) | 2012-09-28 |
Family
ID=8170601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400566A HUP0400566A3 (en) | 2000-12-07 | 2001-12-06 | Pharmaceutical preparation comprising an active dispersed on a matrix |
Country Status (28)
Country | Link |
---|---|
US (2) | US7175854B2 (hu) |
EP (1) | EP1341527B1 (hu) |
JP (1) | JP4950409B2 (hu) |
KR (1) | KR20030072557A (hu) |
CN (2) | CN1523980A (hu) |
AT (1) | ATE519481T1 (hu) |
AU (2) | AU2002216073B2 (hu) |
BR (1) | BR0115987A (hu) |
CA (1) | CA2430828C (hu) |
CY (1) | CY1112333T1 (hu) |
CZ (1) | CZ20031881A3 (hu) |
DK (1) | DK1341527T3 (hu) |
EA (1) | EA007151B1 (hu) |
EE (1) | EE05256B1 (hu) |
ES (1) | ES2371060T3 (hu) |
HR (1) | HRP20030493B1 (hu) |
HU (1) | HUP0400566A3 (hu) |
IL (2) | IL155964A0 (hu) |
MX (1) | MXPA03005092A (hu) |
NO (1) | NO333722B1 (hu) |
NZ (1) | NZ526015A (hu) |
PL (1) | PL206595B1 (hu) |
PT (1) | PT1341527E (hu) |
SG (1) | SG148028A1 (hu) |
SI (1) | SI1341527T1 (hu) |
UA (1) | UA80393C2 (hu) |
WO (1) | WO2002045693A1 (hu) |
ZA (1) | ZA200305114B (hu) |
Families Citing this family (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2754177B1 (fr) * | 1996-10-07 | 1999-08-06 | Sanofi Sa | Microspheres pharmaceutiques d'acide valproique pour administration orale |
UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
BR0115989A (pt) * | 2000-12-07 | 2004-01-13 | Altana Pharma Ag | Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido |
US7988999B2 (en) * | 2000-12-07 | 2011-08-02 | Nycomed Gmbh | Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient |
FR2818552B1 (fr) * | 2000-12-26 | 2003-02-07 | Servier Lab | Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine |
WO2003043614A2 (en) * | 2001-11-19 | 2003-05-30 | Altana Pharma Ag | Reversible proton pump inhibitors for the treatment of airway disorders |
FR2834894B1 (fr) * | 2002-01-21 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible de piribedil |
FR2834896B1 (fr) * | 2002-01-23 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible d'ivabradine |
FR2834890B1 (fr) * | 2002-01-23 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible d'agomelatine |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
AU2003255527A1 (en) * | 2002-06-28 | 2004-01-19 | Speedel Pharma Ag | Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant |
WO2004004690A1 (en) * | 2002-07-03 | 2004-01-15 | Abbott Laboratories | Liquid dosage forms of proton pump inhibitors |
US8877168B1 (en) | 2002-07-31 | 2014-11-04 | Senju Pharmaceuticals Co., Ltd. | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
US20080081834A1 (en) | 2002-07-31 | 2008-04-03 | Lippa Arnold S | Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders |
US20040127541A1 (en) * | 2002-07-31 | 2004-07-01 | Janet Codd | Bicifadine formulation |
US8784789B2 (en) * | 2002-07-31 | 2014-07-22 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
CA2395931A1 (en) * | 2002-08-07 | 2004-02-07 | Bernard Charles Sherman | Solid compositions comprising gabapentin having improved stability |
KR20040016202A (ko) * | 2002-08-16 | 2004-02-21 | 주식회사 제이알팜 | 쓴맛이 차폐된 히드로코르티손 경구용 약제 조성물 및 그제조방법 |
WO2004019937A1 (en) * | 2002-09-02 | 2004-03-11 | Sun Pharmaceutical Industries Limited | Pharmaceutical composition of metaxalone with enhanced oral bioavailability |
UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
US20060014801A1 (en) * | 2002-11-22 | 2006-01-19 | The Johns Hopkins University | Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs |
MXPA04008070A (es) | 2003-03-10 | 2004-11-26 | Altana Pharma Ag | Novedoso proceso para la preparacion de roflumilasto. |
TW200503783A (en) * | 2003-04-11 | 2005-02-01 | Altana Pharma Ag | Oral pharmaceutical preparation for proton pump antagonists |
AR045142A1 (es) * | 2003-07-30 | 2005-10-19 | Novartis Ag | Composicion veterinaria masticable ductil de buen sabor |
US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
BRPI0416566A (pt) | 2003-11-17 | 2007-01-23 | Biomarin Pharm Inc | tratamento de fenilcetonúrias com bh4 |
EP1696881A2 (en) * | 2003-12-23 | 2006-09-06 | Sun Pharmaceutical Industries Limited | Stable oral composition |
KR100629771B1 (ko) * | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
DE102004011512B4 (de) * | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
EA012570B1 (ru) | 2004-03-10 | 2009-10-30 | Шеринг Акциенгезельшафт | Твердая или полутвердая композиция, содержащая молекулярно диспергированный дроспиренон, и способ ее получения |
KR100681660B1 (ko) * | 2004-03-17 | 2007-02-09 | 주식회사종근당 | 방출제어 펠릿의 약제학적 조성물 |
US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
LT2574341T (lt) | 2004-03-29 | 2017-09-11 | University Of South Florida | Navikų ir vėžio efektyvus gydymas triciribino fosfatu |
US20100173864A1 (en) * | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
US20110008327A1 (en) | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
US20100009928A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
CN100345544C (zh) * | 2004-06-10 | 2007-10-31 | 范敏华 | 一种尼麦角林口腔崩解片剂及其制备方法 |
PE20060484A1 (es) * | 2004-07-14 | 2006-07-06 | Ucb Farchim Sa | Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina |
US20080050428A1 (en) * | 2004-10-05 | 2008-02-28 | Altana Pharma Ag | Oral Pharmaceutical Preparation Comprising a Proton Pump Antagonist and a Basic Excipient |
KR101086254B1 (ko) | 2004-11-04 | 2011-11-24 | 에스케이케미칼주식회사 | 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법 |
MX2007005039A (es) * | 2004-11-17 | 2007-06-19 | Biomarin Pharm Inc | Formulacion de tableta estable. |
DE102005009241A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit kontrollierter Bioverfügbarkeit |
US20100047338A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
WO2006099121A2 (en) * | 2005-03-10 | 2006-09-21 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof |
JP5383183B2 (ja) * | 2005-03-16 | 2014-01-08 | タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロフルミラストを含有する矯味された剤形 |
KR100706036B1 (ko) * | 2005-04-04 | 2007-04-11 | 대화제약 주식회사 | 염산 탐술로신 서방성 정제 및 그의 간단한 제조방법 |
JP2008546786A (ja) * | 2005-06-23 | 2008-12-25 | シェーリング コーポレイション | Pde5インヒビターの迅速吸収性経口処方物 |
WO2007011764A2 (en) * | 2005-07-15 | 2007-01-25 | Bayer Schering Pharma Aktiengesellschaft | Drospirenone containing transdermal drug delivery devices and methods of delivery thereof |
EP1762179A1 (en) | 2005-09-07 | 2007-03-14 | Boehringer Ingelheim Vetmedica Gmbh | Method for improving diagnostic quality in echocardiography |
BRPI0616633A2 (pt) * | 2005-09-29 | 2011-06-28 | Bayer Healthcare Ag | inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos |
CN1870631B (zh) * | 2005-11-11 | 2010-04-14 | 华为技术有限公司 | 媒体网关的门控方法 |
PE20070698A1 (es) * | 2005-11-14 | 2007-08-17 | Teijin Pharma Ltd | Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol |
EP1965761B1 (de) * | 2005-12-21 | 2015-07-01 | Basf Se | Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten |
JP2007210905A (ja) * | 2006-02-07 | 2007-08-23 | Asahi Breweries Ltd | 口腔内用顆粒、錠剤およびその製造方法 |
CN1915233B (zh) * | 2006-08-30 | 2012-10-03 | 四川科瑞德制药有限公司 | 一种治疗焦虑症的药物组合物及其口崩制剂 |
WO2008031928A1 (fr) * | 2006-09-14 | 2008-03-20 | Pierre Fabre Medicament | Utilisation du milnacipran pour diminuer les proprietes recompensantes de l'alcool pendant ou apres un traitement de sevrage alcoolique |
EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
KR100815029B1 (ko) * | 2006-11-29 | 2008-03-18 | 부광약품 주식회사 | 독소필린 서방출성 제제 |
GB2461822B (en) * | 2007-03-20 | 2011-09-21 | Isp Investments Inc | Meltable binder for melt granulation and/or pelletization |
AU2008258627A1 (en) * | 2007-06-06 | 2008-12-11 | Basf Se | Pharmaceutical formulation for the production of rapidly disintegrating tablets |
ES2646112T3 (es) * | 2007-06-06 | 2017-12-12 | Basf Se | Formulación farmacéutica para la fabricación de comprimidos que se desintegran rápidamente |
CA2690581A1 (en) * | 2007-06-07 | 2008-12-18 | Dynogen Pharmaceuticals, Inc. | Compositions useful for treating gastroesophageal reflux disease |
AU2009206204B2 (en) * | 2008-01-25 | 2015-03-19 | Alphapharm Pty Ltd | Delayed release pharmaceutical composition of duloxetine |
CN103251631A (zh) * | 2008-05-13 | 2013-08-21 | 根梅迪卡治疗公司 | 用于治疗代谢性病症的水杨酸盐(酯)缀合物 |
US20100040680A1 (en) * | 2008-08-15 | 2010-02-18 | Felix Lai | Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation |
CN102686600A (zh) | 2009-02-05 | 2012-09-19 | 托凯药业股份有限公司 | 甾体cyp17抑制剂/抗雄激素物质的新型药物前体 |
MX2009004635A (es) * | 2009-04-29 | 2010-10-29 | Univ Autonoma Metropolitana | Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades. |
US20110033515A1 (en) * | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
UA102070C2 (uk) * | 2009-12-16 | 2013-06-10 | Общество С Ограниченной Ответственностью "Фармацевтическая Группа "Здоровье" | Застосування фармацевтичної композиції, що містить (s)-2-аміно-5-гуанідинопентанової кислоти (s)-2-аміноглутарат, для лікування і профілактики патологій вагітності |
FR2959130A1 (fr) * | 2010-04-21 | 2011-10-28 | Sanofi Aventis | Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant. |
US20130129791A1 (en) * | 2010-05-04 | 2013-05-23 | Mahmut Bilgic | Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof |
PL2579859T3 (pl) * | 2010-06-14 | 2015-12-31 | Ratiopharm Gmbh | Kompozycja stała zawierająca iwabradynę |
CN101879139A (zh) * | 2010-06-23 | 2010-11-10 | 广西方略药业集团有限公司 | 一种治疗消化性疾病的肠溶制剂及其制备方法 |
CN102309442A (zh) * | 2010-07-07 | 2012-01-11 | 澳美制药厂 | 盐酸氨溴索口服水性组合物及其制备方法 |
CN102309460B (zh) * | 2010-07-09 | 2013-04-24 | 重庆医科大学 | 溴吡斯的明掩味口腔崩解片及其制备方法 |
EP2543364A1 (en) * | 2010-10-14 | 2013-01-09 | Deva Holding Anonim Sirketi | Formulations of cetyl myristate and/or cetyl palmitate |
FR2967067A1 (fr) * | 2010-11-10 | 2012-05-11 | Sanofi Aventis | Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation |
RU2482847C2 (ru) * | 2010-11-17 | 2013-05-27 | Леонид Леонидович Клопотенко | Фармацевтическая композиция, содержащая силденафил или алпростадил, миноксидил или эуфиллин, тестостерон или йохимбин и липосомы для местного применения |
GB201021186D0 (en) | 2010-12-14 | 2011-01-26 | Novabiotics Ltd | Composition |
US9119793B1 (en) | 2011-06-28 | 2015-09-01 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for doxycycline |
AU2012284053A1 (en) * | 2011-07-18 | 2014-01-23 | Tokai Pharmaceuticals, Inc. | Novel compositions and methods for treating prostate cancer |
US9730913B2 (en) * | 2011-10-13 | 2017-08-15 | The Johns Hopkins University | High affinity beta lactamase inhibitors |
US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
US9717678B2 (en) * | 2011-11-06 | 2017-08-01 | Murty Pharmaceuticals, Inc. | Delivery systems for improving oral bioavailability of Fenobam, its hydrates, and salts |
ITMI20112066A1 (it) * | 2011-11-14 | 2013-05-15 | Altergon Sa | Preparazione farmaceutica orale monodose di ormoni tiroidei t3 e t4 |
EP2825159B1 (en) | 2012-03-15 | 2022-06-22 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
CA2881958C (en) * | 2012-08-13 | 2019-08-27 | Adipharm Ead | Pharmaceutical formulations containing 3-(4-cinnamyl-1-piperazinyl) amino derivatives of 3-formylrifamycin sv and 3-formylrifamycin s and a process of their preparation |
CN102988297A (zh) * | 2012-12-21 | 2013-03-27 | 无锡泓兴生物医药科技有限公司 | 罗氟司特固体分散体及含有其的药物组合物 |
EP3763366A1 (en) * | 2013-01-28 | 2021-01-13 | Incozen Therapeutics Pvt. Ltd. | Roflumilast n-oxide for use in treating autoimmune, respiratory and inflammatory disorders by inhalation |
CA2904170A1 (en) | 2013-03-14 | 2014-09-25 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
US10842802B2 (en) | 2013-03-15 | 2020-11-24 | Medicis Pharmaceutical Corporation | Controlled release pharmaceutical dosage forms |
MX2015017651A (es) | 2013-07-11 | 2016-11-14 | Tasly Pharmaceutical Group Co | Formulacion de una pildora por goteo y el metodo de preparacion de la misma. |
HUE058040T2 (hu) | 2013-07-11 | 2022-06-28 | Tasly Pharmaceutical Group Co | Hagyományos kínai gyógyászati kompozíció, és ennek elkészítése és alkalmazása |
CA2916750C (en) | 2013-07-11 | 2023-11-07 | Tasly Pharmaceutical Group Co., Ltd. | Traditional chinese medicine composition, and preparation and application thereof |
WO2015007760A1 (en) | 2013-07-19 | 2015-01-22 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
CN105636594A (zh) | 2013-08-12 | 2016-06-01 | 托凯药业股份有限公司 | 使用雄激素靶向疗法用于***性疾病的生物标记物 |
KR101399514B1 (ko) * | 2013-10-28 | 2014-05-27 | 에스케이케미칼주식회사 | 폴라프레징크를 함유하는 안정한 정제 제형 |
EP3106150B1 (en) | 2013-12-04 | 2021-07-28 | Boehringer Ingelheim Vetmedica GmbH | Improved pharmaceutical compositions of pimobendan |
WO2015132708A1 (en) * | 2014-03-07 | 2015-09-11 | Torrent Pharmaceuticals Limited | Pharmaceutical composition of roflumilast |
CN104434811A (zh) * | 2014-11-07 | 2015-03-25 | 浙江大学 | 一种可嵌于人工晶状体襻上的药物缓释微球及其制备方法 |
US9710054B2 (en) | 2015-02-28 | 2017-07-18 | Intel Corporation | Programmable power management agent |
EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
CN108721242B (zh) * | 2015-06-03 | 2021-03-02 | 南京三迭纪医药科技有限公司 | 药品剂型及其使用 |
ITUB20153652A1 (it) * | 2015-09-16 | 2017-03-16 | Fatro Spa | Microsfere contenenti lattoni macrociclici antielminitici |
AU2017233134A1 (en) | 2016-03-16 | 2018-10-04 | Hanmi Pharm. Co., Ltd. | Dutasteride- and tamsulosin-containing hard capsule complex and preparation method therefor |
US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
EP3308773A1 (en) * | 2016-10-11 | 2018-04-18 | Recordati Industria Chimica E Farmaceutica SPA | Formulations of cysteamine and cysteamine derivatives |
US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
US20200155524A1 (en) | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
WO2019059652A1 (ko) * | 2017-09-19 | 2019-03-28 | 경상대학교 산학협력단 | 맛이 차폐된 경구투여용 약학적 제제 및 이의 제조 방법 |
US11534493B2 (en) | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
US10285998B1 (en) | 2018-04-04 | 2019-05-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
KR20210044191A (ko) | 2018-06-04 | 2021-04-22 | 아큐티스, 인크. | 로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형 |
CN110051633A (zh) * | 2018-11-27 | 2019-07-26 | 宁夏医科大学 | 一种环维黄杨星d纳米制剂及其制备方法 |
CN111840308B (zh) * | 2019-07-18 | 2022-03-01 | 北京市农林科学院 | 6种小分子药物在抑制犬细小病毒中的应用 |
CN111000844B (zh) * | 2019-12-19 | 2022-06-28 | 浙江立恩生物科技有限公司 | 一种治疗流感病毒感染的药物 |
CN115209876A (zh) * | 2020-03-11 | 2022-10-18 | 泽井制药株式会社 | 颗粒和使用该颗粒的制剂 |
US20230372249A1 (en) | 2020-09-04 | 2023-11-23 | Elanco Us Inc. | Palatable formulations |
CN112546000B (zh) * | 2020-12-30 | 2023-06-20 | 海南海神同洲制药有限公司 | 一种盐酸克林霉素棕榈酸酯干混悬剂及其制备方法 |
CN113662920A (zh) * | 2021-09-28 | 2021-11-19 | 南京长澳医药科技有限公司 | 一种比拉斯汀口腔崩解片及其制备方法 |
CN114796127A (zh) * | 2022-05-16 | 2022-07-29 | 北京斯利安药业有限公司 | 伊来西胺缓释干混悬剂及其制备方法 |
US20240108609A1 (en) | 2022-09-15 | 2024-04-04 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3065142A (en) * | 1958-07-30 | 1962-11-20 | Armour Pharma | Gastric resistant medicinal preparation |
US4006227A (en) * | 1973-11-15 | 1977-02-01 | Gallegos Alfred J | Compositions and methods for fertility control |
US4343804A (en) | 1979-03-26 | 1982-08-10 | A. H. Robins Company, Inc. | 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds |
ZA81219B (en) | 1980-01-23 | 1982-01-27 | Schering Corp | Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them |
EP0068378B1 (en) | 1981-06-26 | 1986-03-05 | Schering Corporation | Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them |
US4464372A (en) | 1982-08-16 | 1984-08-07 | Schering Corporation | Imidazo[1,2-b]pyridazines |
GB8305245D0 (en) | 1983-02-25 | 1983-03-30 | Fujisawa Pharmaceutical Co | Imidazo-heterocyclic compounds |
GB8307865D0 (en) | 1983-03-22 | 1983-04-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
GB8415540D0 (en) | 1984-06-18 | 1984-07-25 | Fujisawa Pharmaceutical Co | Imidazoisoquinoline compounds |
US4725601A (en) | 1985-06-04 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers |
JPS625966A (ja) | 1985-07-03 | 1987-01-12 | Nippon Shinyaku Co Ltd | ベンズイミダゾ−ル誘導体 |
EP0228006A1 (en) | 1985-12-16 | 1987-07-08 | Fujisawa Pharmaceutical Co., Ltd. | Imidazopyridine compounds and processes for preparation thereof |
GB8621425D0 (en) | 1986-09-05 | 1986-10-15 | Smith Kline French Lab | Compounds |
US4791117A (en) | 1986-09-22 | 1988-12-13 | Ortho Pharmaceutical Corporation | 2- or 3-aryl substituted imidazo[1,2-a]pyridines and their use as calcium channel blockers |
US4833149A (en) | 1986-09-22 | 1989-05-23 | Ortho Pharmaceutical Corporation | 2- or 3-aryl substituted imidazo[1,2-a]pyridines |
NZ221996A (en) | 1986-10-07 | 1989-08-29 | Yamanouchi Pharma Co Ltd | Imidazo-pyridine derivatives and pharmaceutical compositions |
EP0264883A3 (en) | 1986-10-21 | 1990-04-04 | Banyu Pharmaceutical Co., Ltd. | Substituted pyridine derivatives |
US4831041A (en) | 1986-11-26 | 1989-05-16 | Fujisawa Pharmaceutical Co., Ltd. | Imidazopyridine compounds and processes for preparation thereof |
CA1327796C (en) | 1987-07-16 | 1994-03-15 | Jorg Senn-Bilfinger | Diazoles |
GB8717644D0 (en) | 1987-07-24 | 1987-09-03 | Smithkline Beckman Intercredit | Compounds |
GB8722488D0 (en) | 1987-09-24 | 1987-10-28 | Fujisawa Pharmaceutical Co | Imidazopyridine compound |
GB8804444D0 (en) | 1988-02-25 | 1988-03-23 | Smithkline Beckman Intercredit | Compounds |
WO1990005136A1 (de) | 1988-11-07 | 1990-05-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue imidazopyridine |
KR900014376A (ko) | 1989-03-13 | 1990-10-23 | 후지사와 토모키치로 | 이미다조 피리딘 화합물 및 그것의 제조방법 |
CA2011086A1 (en) | 1989-03-17 | 1990-09-17 | Karl-Heinz Geiss | 2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom |
GB8908229D0 (en) | 1989-04-12 | 1989-05-24 | Smithkline Beckman Intercredit | Compounds |
DE3917232A1 (de) | 1989-05-26 | 1990-11-29 | Basf Ag | 4-arylmethamino-2,3-dialkyl-chinoline, ihre verwendung und daraus hergestellte arzneimittel |
DE3917233A1 (de) | 1989-05-26 | 1990-11-29 | Basf Ag | 8-substituierte 4-(heterocyclylmethylamino)-chinoline, ihre verwendung und daraus hergestellte arzneimittel |
JPH0331280A (ja) | 1989-06-28 | 1991-02-12 | Fujisawa Pharmaceut Co Ltd | 新規イミダゾピリジン化合物 |
FR2657257B1 (fr) | 1990-01-19 | 1994-09-02 | Rhone Poulenc Sante | Procede de preparation de medicaments sous forme de perles. |
DK0480052T3 (da) | 1990-03-28 | 1998-05-11 | Otsuka Pharma Co Ltd | Quinolinderivat, antiulcus-lægemiddel indeholdende derivatet og fremstilling af derivatet |
JP2851117B2 (ja) | 1990-03-30 | 1999-01-27 | 日清製粉株式会社 | インドール誘導体およびそれらを有効成分とする抗潰瘍薬 |
JP2816227B2 (ja) | 1990-03-30 | 1998-10-27 | 日清製粉株式会社 | 抗潰瘍薬 |
IL97931A0 (en) | 1990-04-27 | 1992-06-21 | Byk Gulden Lomberg Chem Fab | Pyridazine derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
US5041442A (en) | 1990-07-31 | 1991-08-20 | Syntex (U.S.A.) Inc. | Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion |
AU8712191A (en) | 1990-10-15 | 1992-05-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | New diazines |
CA2099117A1 (en) | 1991-01-29 | 1992-07-30 | Robert John Ife | Salts of a 4-amino-3-acyl quinoline derivative and their use as inhibitors of gastric acid secretion |
SE9100920D0 (sv) | 1991-03-27 | 1991-03-27 | Astra Ab | New active compounds |
DK0587744T3 (da) | 1991-05-28 | 2003-10-20 | Mcneil Ppc Inc | Tygbar sammensætning til frigørelse af et lægemiddel |
JP3108483B2 (ja) | 1991-09-30 | 2000-11-13 | 日清製粉株式会社 | インドール誘導体およびこれを有効成分とする抗潰瘍薬 |
JP3038064B2 (ja) | 1991-10-07 | 2000-05-08 | 日清製粉株式会社 | インドール誘導体およびこれを有効成分とする抗潰瘍薬 |
WO1993008190A1 (de) | 1991-10-25 | 1993-04-29 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyrrolo-pyridazine mit magen- und darmschutzwirkungen |
GB9126438D0 (en) | 1991-12-12 | 1992-02-12 | Smithkline Beecham Intercredit | New quinoline derivatives |
GB9201692D0 (en) | 1992-01-27 | 1992-03-11 | Smithkline Beecham Intercredit | Compounds |
GB9201694D0 (en) | 1992-01-27 | 1992-03-11 | Smithkline Beecham Intercredit | Compounds |
GB9201693D0 (en) | 1992-01-27 | 1992-03-11 | Smithkline Beecham Intercredit | Compounds |
JP3523275B2 (ja) | 1992-03-26 | 2004-04-26 | 東光薬品工業株式会社 | 貼付剤 |
JP3284622B2 (ja) | 1992-10-23 | 2002-05-20 | ソニー株式会社 | ディスク装置 |
US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
KR0144833B1 (ko) | 1992-12-28 | 1998-07-15 | 김태훈 | 신규의 퀴나졸린 유도체 및 그의 제조방법 |
IL108520A (en) | 1993-02-15 | 1997-09-30 | Byk Gulden Lomberg Chem Fab | 2, 3, 8-TRISUBSTITUTED IMIDAZO £1, 2-a| PYRIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
DK0695303T3 (da) | 1993-04-22 | 2002-03-11 | Byk Gulden Lomberg Chem Fab | Hidtil ukendte pyridiniumsalte og deres anvendelse til bekæmpelse af Helicobacter-bakterier |
US5556863A (en) | 1993-06-11 | 1996-09-17 | Astra Aktiebolag | Compound for gastric acid secretion inhibition |
JP3284686B2 (ja) | 1993-08-30 | 2002-05-20 | 株式会社明電舎 | ブレーキダイナモメータシステムのブレーキトルク制御方式 |
UA48122C2 (uk) | 1993-10-11 | 2002-08-15 | Бік Гульден Ломберг Хеміше Фабрік Гмбх | АЛКОКСІАЛКІЛКАРБАМАТИ ІМІДАЗО[1,2-а]ПІРИДИНІВ, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ |
SE9401197D0 (sv) | 1994-04-11 | 1994-04-11 | Astra Ab | Active compounds |
AU700730B2 (en) | 1994-07-28 | 1999-01-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Imidazopyridine-azolidinones |
JPH0959152A (ja) | 1995-08-18 | 1997-03-04 | Teisan Seiyaku Kk | 硝酸イソソルビド含有貼付剤 |
SE512835C2 (sv) | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
US5677302A (en) * | 1996-02-26 | 1997-10-14 | Apotex Inc. | Thiadiazole compounds useful as proton pump inhibitors |
US6114537A (en) | 1996-02-26 | 2000-09-05 | Apotex Inc. | Process for scavenging thiols |
US5762953A (en) | 1996-08-22 | 1998-06-09 | Theratech, Inc. | Transdermal propentofylline compositions for the treatment of Alzheimers disease |
SE9700661D0 (sv) | 1997-02-25 | 1997-02-25 | Astra Ab | New compounds |
WO1998042707A1 (en) | 1997-03-24 | 1998-10-01 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tetrahydropyrido compounds |
CA2289542A1 (en) | 1997-05-28 | 1998-12-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Fused dihydropyrans |
IT1294748B1 (it) | 1997-09-17 | 1999-04-12 | Permatec Tech Ag | Formulazione per un dispositivo transdermico |
AU751066B2 (en) * | 1997-12-08 | 2002-08-08 | Nycomed Gmbh | Novel administration form comprising an acid-labile active compound |
SE9801526D0 (sv) | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
CA2319495A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
SE9802793D0 (sv) | 1998-08-21 | 1998-08-21 | Astra Ab | New compounds |
SE9802794D0 (sv) | 1998-08-21 | 1998-08-21 | Astra Ab | New compounds |
JP4370429B2 (ja) | 1998-09-10 | 2009-11-25 | 東和薬品株式会社 | 徐放性マイクロスフエアの製造法 |
EE04677B1 (et) | 1998-09-23 | 2006-08-15 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tetrahdropridoeetrid, nende kasutamine ja ravim |
CA2349476A1 (en) | 1998-11-03 | 2000-05-11 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Imidazonaphthyridines |
PT1173439E (pt) | 1999-04-17 | 2003-10-31 | Altana Pharma Ag | Haloalcoxi imidazonaftiridinas |
DE19925710C2 (de) * | 1999-06-07 | 2002-10-10 | Byk Gulden Lomberg Chem Fab | Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer |
DE60021570T2 (de) * | 1999-06-07 | 2006-05-24 | Altana Pharma Ag | Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor |
UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
DK1341528T3 (da) * | 2000-12-07 | 2012-03-26 | Nycomed Gmbh | Hurtigtopløsende tablet omfattende en syrelabil aktiv bestanddel |
BR0115989A (pt) * | 2000-12-07 | 2004-01-13 | Altana Pharma Ag | Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido |
-
2001
- 2001-06-12 UA UA2003076286A patent/UA80393C2/uk unknown
- 2001-12-06 EP EP01999359A patent/EP1341527B1/en not_active Expired - Lifetime
- 2001-12-06 MX MXPA03005092A patent/MXPA03005092A/es active IP Right Grant
- 2001-12-06 CZ CZ20031881A patent/CZ20031881A3/cs unknown
- 2001-12-06 NZ NZ526015A patent/NZ526015A/xx not_active IP Right Cessation
- 2001-12-06 BR BR0115987-9A patent/BR0115987A/pt not_active Application Discontinuation
- 2001-12-06 KR KR10-2003-7007647A patent/KR20030072557A/ko active Search and Examination
- 2001-12-06 WO PCT/EP2001/014307 patent/WO2002045693A1/en active Application Filing
- 2001-12-06 CN CNA018223818A patent/CN1523980A/zh active Pending
- 2001-12-06 ES ES01999359T patent/ES2371060T3/es not_active Expired - Lifetime
- 2001-12-06 CN CN201010149221A patent/CN101810592A/zh active Pending
- 2001-12-06 AT AT01999359T patent/ATE519481T1/de active
- 2001-12-06 EE EEP200300235A patent/EE05256B1/xx not_active IP Right Cessation
- 2001-12-06 SI SI200131002T patent/SI1341527T1/sl unknown
- 2001-12-06 PL PL362323A patent/PL206595B1/pl unknown
- 2001-12-06 AU AU2002216073A patent/AU2002216073B2/en not_active Ceased
- 2001-12-06 PT PT01999359T patent/PT1341527E/pt unknown
- 2001-12-06 AU AU1607302A patent/AU1607302A/xx active Pending
- 2001-12-06 EA EA200300634A patent/EA007151B1/ru not_active IP Right Cessation
- 2001-12-06 DK DK01999359.1T patent/DK1341527T3/da active
- 2001-12-06 CA CA2430828A patent/CA2430828C/en not_active Expired - Fee Related
- 2001-12-06 US US10/433,398 patent/US7175854B2/en not_active Expired - Fee Related
- 2001-12-06 JP JP2002547479A patent/JP4950409B2/ja not_active Expired - Fee Related
- 2001-12-06 SG SG200503573-8A patent/SG148028A1/en unknown
- 2001-12-06 IL IL15596401A patent/IL155964A0/xx unknown
- 2001-12-06 HU HU0400566A patent/HUP0400566A3/hu not_active Application Discontinuation
-
2003
- 2003-05-18 IL IL155964A patent/IL155964A/en not_active IP Right Cessation
- 2003-06-06 NO NO20032593A patent/NO333722B1/no not_active IP Right Cessation
- 2003-06-17 HR HR20030493A patent/HRP20030493B1/xx not_active IP Right Cessation
- 2003-07-01 ZA ZA200305114A patent/ZA200305114B/en unknown
-
2006
- 2006-12-21 US US11/642,621 patent/US7951398B2/en not_active Expired - Fee Related
-
2011
- 2011-10-31 CY CY20111101018T patent/CY1112333T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0400566A3 (en) | Pharmaceutical preparation comprising an active dispersed on a matrix | |
GB0014074D0 (en) | Active matrix array devices | |
HUP0300530A3 (en) | Hydrophilic/lipophilic polymeric matrix dosage formulation | |
GB0104786D0 (en) | Active Matrix Device | |
GB9706942D0 (en) | Active matrix devices | |
AU2002241548A1 (en) | A bilayer structure which encapsulates multiple containment units and uses thereof | |
GB0031039D0 (en) | Active matrix devices | |
HK1045465B (zh) | 包含美格拉坦及其前體藥物的藥用製劑 | |
GB0000290D0 (en) | Active matrix electroluminescent display device | |
HUP0301177A3 (en) | Ion-strength independent sustained release pharmaceutical formulation | |
GB9914808D0 (en) | Active matrix electroluminscent device | |
AUPQ761100A0 (en) | Lipophilic medicament | |
HUP0303860A3 (en) | A pharmaceutical tablet having a high active ingredient | |
HK1046501A1 (en) | Pharmaceutical agent comprising a benzamide derivative as active ingredient. | |
ZA200304928B (en) | Medicament containing a polyamine as an active substance. | |
EP1189195A3 (en) | Active matrix display device | |
AU2001232244A1 (en) | Drug comprising combination | |
GB9917677D0 (en) | Active matrix array devices | |
HUP0600143A2 (en) | A stable pharmaceutical formulation comprising torsemide modification ii | |
GB0121524D0 (en) | Active matrix display | |
EP1205787A3 (en) | Active matrix display device | |
GB0125019D0 (en) | Active matrix display device | |
GB0119653D0 (en) | Active matrix display device | |
AU2002218159A1 (en) | Transparent active substance capsules | |
GB0020999D0 (en) | Active matrix display device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB9A | Succession in title |
Owner name: NYCOMED GMBH, DE Free format text: FORMER OWNER(S): ALTANA PHARMA AG, DE |
|
HC9A | Change of name, address |
Owner name: TAKEDA GMBH, DE Free format text: FORMER OWNER(S): ALTANA PHARMA AG, DE; NYCOMED GMBH, DE |
|
FC4A | Lapse of provisional application due to refusal |